Relationship between IGF-1 and body weight in inflammatory bowel diseases: Cellular and molecular mechanisms involved
Inflammatory bowel diseases (IBD), represented by ulcerative colitis (UC) and Crohn's disease (CD), are characterized by chronic inflammation of the gastrointestinal tract, what leads to diarrhea, malnutrition, and weight loss. Depression of the growth hormone-insulin-like growth factor-1 axis...
Enregistré dans:
Auteurs principaux: | Luis G. Guijarro, David Cano-Martínez, M.Val Toledo-Lobo, Patricia Sanmartín Salinas, María Chaparro, Ana M. Gómez-Lahoz, Sofía Zoullas, Rosa Rodríguez-Torres, Irene D. Román, Laura Sebastián Monasor, Lidia Ruiz-Llorente, María del Carmen Boyano-Adánez, Iván Guerra, Marisa Iborra, José Luis Cabriada, Luis Bujanda, Carlos Taxonera, Valle García-Sánchez, Ignacio Marín-Jiménez, Manuel Barreiro-de Acosta, Isabel Vera, María Dolores Martín-Arranz, Francisco Mesonero, Laura Sempere, Fernando Gomollón, Joaquín Hinojosa, Melchor Alvarez-Mon, Javier P. Gisbert, Miguel A. Ortega, Borja Hernández-Breijo, on behalf of the PREDICROHN study group from GETECCU |
---|---|
Format: | article |
Langue: | EN |
Publié: |
Elsevier
2021
|
Sujets: | |
Accès en ligne: | https://doaj.org/article/07a4ccf32ca74a43a9db582d7fa13f0a |
Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
Documents similaires
-
Efficacy of adalimumab as second-line therapy in a pediatric cohort of Crohn’s disease patients who failed infliximab therapy: the Italian Society of Pediatric Gastroenterology, Hepatology, and Nutrition experience
par: Alvisi P, et autres
Publié: (2019) -
A Rare Infectious Complication of a Treatment with Biologics: Disseminated Cutaneous Leishmaniasis Associated with Adalimumab
par: Kerasia-Maria Plachouri, et autres
Publié: (2020) -
Adalimumab Therapy in a Patient with Psoriasis, Down Syndrome, and Concomitant Hepatitis B Virus Infection
par: Madani A, et autres
Publié: (2021) -
A Practical Guide to Therapeutic Drug Monitoring of Biologic Medications for Inflammatory Bowel Disease
par: Byron P. Vaughn
Publié: (2021) -
Secukinumab: Rapid Efficacy in Psoriasis After Primary Failure With Ustekinumab and Adalimumab
par: Aline Lissa Okita, et autres
Publié: (2020)